Companies / Apellis Pharmaceuticals, Inc. / Activity
Activity — Apellis Pharmaceuticals, Inc.
60 moves.
Top impactInsider · CEO movesInsider · biggest buysInsider · biggest sellsInstitution · biggest movesInstitution · new positions
| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Jan 1, 2026 | Fonteyne Paul R. Director | Grant | Stock Option (Right to Buy) | — | +15K | 14,684 0.01% of shares | low |
| Jan 1, 2026 | Dunlop A. Sinclair Director | Grant | Stock Option (Right to Buy) | — | +15K | 14,684 0.01% of shares | low |
| Jan 1, 2026 | O'Brien Stephanie Monaghan Director | Grant | Stock Option (Right to Buy) | — | +15K | 14,684 0.01% of shares | low |
| Feb 3, 2026 | Francois Cedric CEO | Exercise | Stock Option (Right to Buy) | — | -9K -100.00% | 0 0.00% of shares | low |
| Jan 7, 2026 | Watson David O. Executive | Exercise | Stock Option (Right to Buy) | — | -888 -5.96% | 14,000 0.01% of shares | low |
| Jan 1, 2026 | Chan Gerald Director | Grant | Stock Option (Right to Buy) | — | +15K | 14,684 0.01% of shares | low |
| Jan 1, 2026 | Machiels Alec Director | Grant | Stock Option (Right to Buy) | — | +15K | 14,684 0.01% of shares | low |
| Feb 27, 2026 | Dolsten Mikael Director | Grant | Stock Option (Right to Buy) | — | +24K | 24,135 0.02% of shares | low |
| Jan 1, 2026 | Walbert Keli Director | Grant | Stock Option (Right to Buy) | — | +15K | 14,684 0.01% of shares | low |
| Jan 1, 2026 | Wheeler Craig a Director | Grant | Stock Option (Right to Buy) | — | +15K | 14,684 0.01% of shares | low |